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Abstract: In this study, zinc phthalocyanine (ZnPc) was loaded onto poly-ε-caprolactone 
(PCL) nanoparticles (NPs) using a solvent emulsification–evaporation method. The process 
yield and encapsulation efficiency were 74.2% ± 1.2% and 67.1% ± 0.9%, respectively. The NPs 
had a mean diameter of 187.4 ± 2.1 nm, narrow distribution size with a polydispersity index 
of 0.096 ± 0.004, zeta potential of −4.85 ± 0.21 mV , and spherical shape. ZnPc has sustained 
release, following Higuchi’s kinetics. The photobiological activity of the ZnPc-loaded NPs 
was evaluated on human lung adenocarcinoma A549 cells. Cells were incubated with free ZnPc 
or ZnPc-loaded NPs for 4 h and then washed with phosphate-buffered saline. Culture medium 
was added to the wells containing the cells. Finally, the cells were exposed to red light (660 nm) 
with a light dose of 100 J/cm2. The cellular viability was determined after 24 h of incubation. 
ZnPc-loaded NPs and free photosensitizer eliminated about 95.9% ± 1.8% and 28.7% ± 2.2% 
of A549 cells, respectively. The phototoxicity was time dependent up to 4 h and concentration 
dependent at 0–5 µg ZnPc. The cells viability decreased with the increase of the light dose in 
the range of 10–100 J/cm2. Intense lysis was observed in the cells incubated with the ZnPc-
loaded NPs and irradiated with red light. ZnPc-loaded PCL NPs are the release systems that 
promise photodynamic therapy use.
Keywords: photosensitizer, nanoparticles, photodynamic therapy, lung cancer, phototoxicity, 
biodistribution
Introduction
Photodynamic therapy (PDT) is being actively exploited in many clinical applications 
such as cancer treatment, age-related macular degeneration, and infection.1,2 PDT is 
based on the administration of drugs known as photosensitizers that are taken up and/
or retained by neoplastic tissues.3,4 The photosensitizers alone are harmless and ideally 
have no effect on either healthy or abnormal tissues. After a predefined time interval 
that allows photosensitizer accumulation in the tumor tissue, the illumination of the 
tumor site with nonthermal light (600–800 nm) leads to the formation of an excited 
photosensitizer. The combined action of the excited triplet photosensitizer and molecu-
lar oxygen results in the formation of singlet oxygen (1O2), which is the main mediator 
of cellular death induced by PDT.2 PDT has been shown to induce both apoptosis 
(slow process)5 and necrosis (drastic process).3 Among the most promising second-
generation photosensitizers for PDT are the phthalocyanines. In this study, zinc 
phthalocyanine (ZnPc), a metallophthalocyanine, was used because of its very International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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strong phototoxicity effect,6 easy availability, and low cost. 
ZnPc is stable and produces 1O2 with high yield.7 However, 
ZnPc is lipophilic and slightly soluble in water or in a physi-
ologically acceptable vehicle. This hydrophobic characteristic 
hinders its systemic administration and restricts its clinical 
studies.
ZnPc is a dye and photosensitizer with molecular weight 
of 577.91 g/mol. It is a crystalline powder, lipophilic, and 
soluble in pyridine, dimethylsulfoxide, dimethylformamide, 
and dichloromethane (DCM).8 The photosensitizer can be 
dissolved in dimethylsulfoxide and diluted with ethanol. 
However, it suffers aggregation in water with reduction of 
its photobiological activity.9 It exhibits a high thermal stability, 
and ,5% of its mass is lost at 500°C.9 ZnPc has strong 
absorbance in the red region of the spectrum of visible light 
(λmax = 666 nm in ethanol). It has strong fluorescence emis-
sion in the range of 650–800 nm.9 Methylene blue (MB) is 
a hydrophilic dye and photosensitizer.10 In this study, it was 
used as a positive control of the photobiological activity. 
It exhibits strong absorbance in the red region (λmax = 656 nm 
in water) and fluorescence emission (λmax = 656 nm)10 similar 
to ZnPc.
Nanoparticles (NPs) are promising delivery systems for 
use in PDT. These systems provide sustained release, avoid 
plasmatic fluctuations, decrease side effects, reduce the 
frequency of administration, and enhance the uptake of drugs 
by targeted tissue, increasing the treatment effectiveness.2,11–14 
Advances in nanobiotechnology have resulted in the develop-
ment of several colloidal carrier systems such as NPs to 
achieve these multiple objectives.2,4 The encapsulation of 
hydrophobic drugs in NPs is a viable alternative in solving 
the solubility problem,12 besides promoting targeted delivery 
and sustained release. The liposomes and the nanoemulsions 
are examples of drugs carrier. However, they have problems 
of physical stability. The liposomes can suffer disruption and 
have limited capacity to encapsulate lipophilic drugs.15 
Nanoemulsions can suffer creaming, flocculation, and coales-
cence. NPs have excellent physical stability, provide protec-
tion of the actives, and sustain drugs release.15
NPs have been used as a vehicle for the delivery of PDT 
agents.2,4,16,17 Several photosensitizers, many of which are 
hydrophobic, have been encapsulated in polyesters, such as 
poly(lactic-co-glycolic acid) and polylactic acid NPs, to 
overcome the problems associated with solubilization.12 
For example, meso-tetra(4-hydroxyphenyl) porphyrin,18,19 
  bacteriochlorophyll-a,20 verteporfin,21 MB,22 hypericin,23 and 
various phthalocyanines9,24 have all been encapsulated in such 
polyesters. Several studies have proved that the NPs are prom-
ising delivery systems for photosensitizers. Generally, pho-
tosensitizers loaded in NPs induce better phototoxicity than 
free photosensitizers.18,23 Moreover, encapsulation in NPs 
decreases the aggregation of the photosensitizer in solution20 
or in physiologically acceptable vehicles.
Biocompatible and biodegradable polymers can be used 
to produce NPs. Much attention has been focused on poly-
ε-caprolactone (PCL), a semicrystalline polyester.9,25–27 This 
polymer has been used in the development of release systems 
such as microparticles and NPs.25–27 PCL NPs have been used 
as delivery systems of isradipine,28 primidone,29 paclitaxel,30 
griseofulvin,31 tamoxifen,32 espironolactone,33 vinblastine,34 
and docetaxel.35
The aim of this study was to load ZnPc in PCL NPs to 
improve the photobiological activity of the photosensitizer. 
NPs were produced and characterized in terms of their size, 
charge, morphology, and encapsulation efficiency (EE). 
In vitro release studies were carried out to evaluate the 
photosensitizer release profile and kinetic study. The pho-
tobiological activity of the ZnPc-loaded NPs and free pho-
tosensitizer were assessed on human lung adenocarcinoma 
A549 cancer cells.
Material and methods
Materials
ZnPc (MW = 577.91), MB (MW = 373.90) ($82%), hydro-
lyzed polyvinyl alcohol (PVA) (87%–89%) (MW = 13,000–
23,000), 9,10-anthracenediyl-bis(methylene)dimalonic acid 
(ABMDMA), 3-(4,5-dimethyl-thiazol-2-yl)-2,5-biphenyl 
tetrazolium bromide (MTT), and PCL (MW = 42,500–65,000) 
were purchased from Sigma-Aldrich (St. Louis, MO). DCM 
and acetone were purchased from Merck (Darmstadt, 
  Germany). Sodium dodecyl sulfate (SDS), NaCl, KCl, 
NaH2PO4, and Na2HPO4 were purchased from Vetec (Duque 
de Caxias, Brazil). Uranyl acetate was purchased from 
  Reagem (Colombo, Brazil). The following cell culture items 
were purchased from Gibco Invitrogen (New York, NY): 
Dulbecco’s modified Eagle’s medium (DMEM), glutamine, 
fetal bovine serum (FBS), sodium bicarbonate, sodium 
hydroxide, and Pen Strep (penicillin 10,000 units/mL + 
streptomycin 10,000 µg/mL in aqueous solution).
NPs preparation and process yield (%)
NPs were prepared by the emulsification and solvent evapo-
ration method. Briefly, ZnPc (3 mg) and PCL (97 mg) were 
dissolved in the DCM (8 mL). The organic solution was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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emulsified in 50 mL of aqueous solution of PVA (1.5%, w/w), 
for 5 min using an ultrasonicator UP100H (100 W, 30 kHz) 
(Hielscher, Teltow, Germany) in an ice bath. PVA is a bio-
compatible polymer and has the function of a surfactant. 
DCM was evaporated under reduced pressure using a rota 
vapor (Heidolph, Schwabach, Germany) at room temperature 
(28°C). The NPs were purified thrice by centrifugation at 
20,000 g (Avanti J-25; Beckman Coulter, San Francisco, 
CA) for 20 min followed by resuspension in water to remove 
the surfactant. NPs were then transferred into glass vials, 
frozen in a liquid nitrogen bath, and lyophilized (Lyophilizer, 
FreeZone 4.5-L Benchtop Freeze Dry System; Labconco, 
Kansas City, MO). The lyophilized powder was stored at 
room temperature (28°C) before analysis.
The process yield (%, w/w) was calculated by Eq. 1:
 
Y
M
M
%, () =× 1
2
100   (1)
where Y(%) is the process yield, M1 is the mass of recovered 
lyophilized powder, and M2 is the mass of the formulation 
(PCL and ZnPc).
characterization
NPs were characterized in terms of their size, polydispersity 
index (PI), morphology, surface charge, EE, and drug content 
(DC). The size and PI were determined by photon correlation 
spectroscopy using a Zetasizer 5000 (Malvern Instruments, 
Malvern, UK). Before measurements, the lyophilized pow-
ders were diluted using purified water. The surface charge 
(zeta potential) was measured using the electrophoretic mode 
with the Zetasizer 5000. The lyophilized powder was dis-
persed in water. The pH of the suspension was measured at 
room temperature (28°C). Morphology was evaluated by 
transmission electron microscopy (TEM) (Morgagni 268; 
FEI, Hillsboro, OR). Lyophilized powder was dispersed in 
water and 5 µL was transferred to a grid. Uranyl acetate 
solution (3%) was added for fixing and contrast. After 30 sec, 
excess liquid was removed using filter paper (Whatman; 
Maidstone, Kent, UK). Grids were placed in vacuum desic-
cators (Pyrex; Corning, Lowell, MA) before analysis.
The drug extraction method from NPs was patronized for 
determination of the EE and DC. The lyophilized powder 
was added in hot acetone (45°C) for disruption of the NPs 
and dissolution of the photosensitizer. The organic solution 
was sonicated for 10 min using an ultrasonic bath (T14; 
Thornton, Vinhedo, São Paulo, Brazil). The organic solution 
was diluted in phosphate-buffered saline (PBS) containing 2% 
SDS to precipitate the polymer (PCL) and to extract the pho-
tosensitizer. The suspension was centrifuged, filtered through 
a membrane filter (0.45 µm, Millex-FH50 filter unit; Millipore, 
Billerica, MA) to remove the PCL, and quantified by fluores-
cence emission. The photosensitizer was diluted in PBS con-
taining 2% SDS at concentrations of 20–200 ng/mL. The 
solutions were excited at 610 nm, and fluorescence emission 
was measured at 680 nm using a Jasco FP-750 fluorimeter 
(Jasco Corporation, Tokyo, Japan). The determination coef-
ficient (R2) exceeded 0.999, with excellent linearity. Intraday 
and interday precision and accuracy of the method showed a 
variation coefficient and a relative error (E) not .2.3% and 
3.1%, respectively.
EE was calculated from Eq. 2:
 
EE %, () =×
M
M
3
4
100   (2)
where EE(%) is the encapsulation efficiency, M3 is the mass 
of ZnPc measured in lyophilized powder, and M4 is the mass 
of photosensitizer used in formulation.
DC in the NPs (µg ZnPc/mg NP) was calculated from 
Eq. 3:
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where DC is the drug content, M5 is the mass (µg) of ZnPc 
measured in lyophilized powder, and M6 is the mass (mg) of 
the lyophilized NP.
In vitro releasing studies and kinetic
A known amount of NPs (50 mg NP containing 1 mg of 
ZnPc) was dispersed in 60 mL of PBS containing 0.5% SDS, 
with pH 7.4, kept at 37°C in a thermostatic bath (M214M2; 
Quimis, Diadema, São Paulo, Brazil). The acceptor solution 
was stirred with a magnetic stirrer at a constant rate of 
300 rpm using a stirrer (M15; Marte, Santa Rita do Sapucaí, 
Minas Gerais, Brazil). At given time intervals, six samples 
(n = 6) of 3 mL were withdrawn and centrifuged at 20,000 g 
for 20 min. The precipitates were resuspended in 3 mL of 
fresh medium and placed in the respective dissolution ves-
sels. The released photosensitizer was quantified by fluores-
cence emission. The in vitro release profile was obtained by 
correlating time (h) versus drug release (%).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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After 240 h of release studies, the acceptor solution 
containing the NPs was removed from the dissolution vessel 
and centrifuged thrice at 20,000 g for 20 min to recover 
the nanostructured system. The NPs were lyophilized, and 
the photosensitizer content was determined by fluorescence 
emission. The extraction and quantification of the photosen-
sitizer of the lyophilized NPs have been described in the 
‘Characterization’ section.
The release data were fitted using the mathematical 
models of zero order, first order, Higuchi, Hixon–Crowell, 
square root of mass, three seconds root of mass, and Baker–
Lonsdale.36,37 Equations of the mathematical modeling are 
shown in Table 1. The data were fitted, and the linear regres-
sion was assessed. The correlation coefficient (r) and R2 were 
compared to determine the mathematical model that best fits 
the release data.
In vitro photobiological activity
The human lung adenocarcinoma cell line (A549)38 was 
chosen for evaluation of the photobiological activity. The 
cells were thawed and placed in DMEM supplemented with 
10% FBS. Penicillin (100 units/mL) and streptomycin 
(100 µg/mL) were added to the culture medium. The medium 
was maintained at 37°C in a 5% CO2 atmosphere for 48 h. 
Cell concentrations were determined by the exclusion test of 
trypan blue using a Neubauer counting chamber.   Aliquots of 
1 × 105 cells/mL were placed into 96-well dishes containing 
250 µL of culture medium. The cell culture was incubated for 
24 h at 37°C in a 5% CO2 atmosphere before examination of 
the toxicity and phototoxicity of the free photosensitizer, and 
the photosensitizer was loaded in NPs.
An NP suspension was prepared in culture medium 
(DMEM) at 1 mg/mL. The cells were washed with PBS 
and incubated with 250 µL of the NP suspension (dose = 5 µg 
of ZnPc) at 37°C in a 5% CO2 atmosphere for 4 h. After 
  incubation, the cells were washed twice with PBS and fresh 
culture medium (250 µL) was added in each well. Finally, 
after cellular uptake of the free ZnPc or ZnPc-loaded NPs, the 
cells were exposed to red light (660 nm) for 90 sec, with a 
light dose of 100 J/cm2 (Photon Lase I; DMC, São Carlos, São 
Paulo, Brazil). After light exposure, the cell culture was incu-
bated for 24 h at 37°C in a 5% CO2 atmosphere, and the 
cellular viability was determined by MTT assay. The NP 
suspension without photosensitizer (empty NPs), control 
(PBS) solution, and photosensitizer solution were also 
assessed in the phototoxicity studies. The dark toxicity 
was also assessed with the same samples. The photobiologi-
cal activity of the light was evaluated. The cell culture was 
exposed to red light (660 nm) with light dose of 0–100 J/cm2, 
and cell viability was determined by the MTT assay. Briefly, 
after removing the cell medium, 50 µL of MTT solution 
(1 mg/mL) was added to each well and incubated for 3 h.39 
Then, the formazan crystals were dissolved with 100 µL of 
10% SDS in 0.01 M HCl in each well.39 The absorbance was 
determined at 595 nm by a microplate reader. For each sample, 
the cellular viability was calculated from the data of 10 wells 
(n = 10) and expressed as a percentage, compared with the 
untreated cells (100%). Comparison of the mean optical den-
sity between the untreated (100%) and treated cells 24 h after 
illumination allowed the evaluation of the phototoxicity.
MB was used as a positive control of the photobiological 
activity. The influence of different parameters on the in vitro 
phototoxicity was investigated by varying the time (1–6 h), 
concentration of photosensitizer (0–10 µg), and light dose 
(0–100 J/cm2).
Morphological evaluation
Aliquots of 1 × 105 cells/mL were placed in 24-well dishes 
containing culture medium. A coverslip was placed on the 
bottom of the well for growth of cells in monolayer. The cell 
culture was incubated for 24 h at 37°C in a 5% CO2 atmo-
sphere before phototoxicity assay. The cells were washed 
with PBS and incubated with NPs suspension (dose = 5 µg 
of ZnPc) (at 37°C in a 5% CO2 atmosphere) for 4 h. After 
incubation, the cells were washed twice with PBS. Culture 
medium was added in each culture plate. Finally, the cells 
were exposed to red light (660 nm) for 90 sec (light dose of 
100 J/cm2) and incubated for 24 h (at 37°C in a 5% CO2 
atmosphere) before microscopic analysis. The empty NPs 
and control solution (PBS) were also assessed.
For microscopic analysis, the cells were fixed in Bouin’s 
liquid for 5 min and washed with alcohol (70%, v/v) and water 
Table  1  Mathematical  models  used  for  linearization  of  the 
photosensitizer release profile data
Mathematical models Equation
Zero order F = k0t
First order ln(1 − F) = −kft
higuchi F = kht1/2
Baker–Lonsdale 3/2[1 − (1 − F)2/3] − F = k3/2t
hixon–crowell 1 − (1 − F)1/3 = k1/3t
Square root of mass 1 − (1 − F)1/2 = k1/2t
Three seconds root of mass 1 − (1 − F)2/3 = k2/3t
Notes: F denotes fraction (%) of drug released up to time t. k0, kf, kh, k3/2, k1/3, k1/2, 
and k2/3 are constants of the mathematical models.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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to remove the fixative solution. The cells were stained with 
Giemsa’s liquid for 2 h.40 Then, the cells were treated and 
dehydrated with glacial acetic acid, acetone, acetone–xylene 
(7:3, v/v), acetone–xylene (1:1, v/v), acetone–xylene (3:7, v/v), 
and xylene. The coverslips were dried and mounted on glass 
slides for observation under light microscope (DML30; Leica, 
Bannockburn, IL). The morphology was evaluated for detec-
tion of changes in the cytoplasm and nucleus.
1O2 detection by photobleaching
The  1O2 generation was determined by photobleaching of 
the chemical probe ABMDMA. It is a water-soluble derivative 
of anthracene that can react with 1O2 to yield an endoperoxide, 
which causes a decrease in the ABMDMA absorption.41 The 
reaction was monitored spectrophotometrically by recording 
the decrease in absorption at 400 nm (wavelength of maxi-
mum absorption). In this study, 0.15 mM of the sodium salt 
of ABMDMA in water was mixed with 5 µg of the encap-
sulated ZnPc or free ZnPc. The empty NPs were used as 
control. The solution was irradiated with red light (660 nm) 
(Photon Lase I; DMC) in an open quartz cell with continuous 
stirring. The absorbance measurements followed by irradia-
tion were carried out every 60 sec.
Statistical analysis
The encapsulation method, process yield, size, PI, surface charge, 
EE, DC, and 1O2 detection by photobleaching were accomplished 
in triplicate (n = 3). The in vitro release studies and kinetics were 
carried out to six determinations (n = 6). The cellular viability 
was calculated from the data of 10 wells (n = 10) and expressed 
as a percentage, compared with the untreated cells (100%). All 
results were expressed as the means ± standard deviation. The 
statistical comparisons of the photobiological activity were 
performed using Student’s t-test. The differences were consid-
ered significant at a level of P , 0.05.
Results
The process yields of the empty NPs and ZnPc-loaded NPs 
were 73.5% ± 1.8% and 74.2% ± 1.2% (w/w), respectively. 
The EE of ZnPc in PCL NPs was about 67.1% ± 0.9%. 
Besides, the ZnPc content of NPs was 20.1 ± 0.07 µg/mg. 
The ZnPc-loaded NPs had an average size of 187.4 ± 2.1 nm. 
Compared with empty NPs (179 ± 1.5 nm), photosensitizer-
loaded NPs had a larger size. IP of the empty NPs and 
ZnPc-loaded NPs was of 0.102 ± 0.02 and 0.096 ± 0.004, 
respectively. The empty NPs and ZnPc-loaded NPs 
  exhibited negative zeta potential of −3.4 ± 0.08 and 
−4.85 ± 0.21 mV , respectively. The morphology of the particles 
was examined by TEM and is shown in Figure 1. The ZnPc-
loaded NPs were spherical (Figure 1A). Figure 1C shows the 
PCL NPs, which were isolated and magnified. Figures 1B and 
1D are photomicrographs of empty NPs.
The in vitro release studies are shown in Figure 2A. ZnPc 
has a sustained release. Besides, 22% of the photosensitizer 
was released from the NPs in 240 h.
After in vitro release studies, the remaining content (%) 
of ZnPc in the PCL NPs was assessed to compare with 
released photosensitizer in the acceptor solution. Table 2 
shows the data of the total of the released ZnPc and the 
remaining content (%, w/w) of ZnPc in the PCL NPs. The 
remaining content of the drug in the NPs confirms and vali-
dates the release data, showing that in vitro release studies 
were suitable for the delivery system.
Several mathematical models were used to investigate 
the mechanism of drug release from PCL NPs. Thus, linear 
regression of the release data was performed using the math-
ematical models of zero order, first order, Higuchi, Hixon–
Crowell, square root of mass, three seconds root of mass, 
and Baker–Lonsdale. The R2 and r values obtained after linear 
regression are shown in Table 3.
Kinetic models were established to describe the release 
kinetics and understand the mechanism of drug release from 
delivery systems.36,37 As shown in Table 3 and Figure 2B, 
the Higuchi model gave the highest value of R2 and r, indicat-
ing that this mathematical model was the most suitable for 
200 nm
200 nm 200 nm
200 nm
AB
CD
Figure 1 Photographs of TeM. A) and C) ZnPc-loaded PcL nanoparticles; B) and 
D) empty nanoparticles.
Abbreviations: TeM, transmission electron microscopy; ZnPc, zinc phthalocyanine; 
PcL, poly-ε-caprolactone.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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describing the release of the photosensitizer from PCL NPs. 
These results suggest that the release of ZnPc from PCL NPs 
is controlled by diffusion.
The photobiological activity at different incubation times 
of free ZnPc, free MB, and ZnPc-loaded NPs is shown in 
Figure 3. No toxicity was observed in the dark. The photo-
toxicity was time dependent up to 4 h. No significant differ-
ence (P . 0.05) in the phototoxicity of the encapsulated ZnPc 
was observed for the incubation time of 4 and 6 h. Thus, the 
incubation time of 4 h was chosen for other   phototoxicity 
studies (influence of the light dose and concentration). The 
cell viability of the free ZnPc slowly decreased in the range 
1–6 h. The photobiological activity of the MB was observed 
after 2 h of incubation with activity maximum in 6 h. ZnPc-
loaded NPs exhibited phototoxicity significantly higher than 
free photosensitizers (P , 0.05) (Figure 3).
The photobiological activity of different concentrations 
of ZnPc-loaded NPs was evaluated in cell cultures and 
  compared with the free photosensitizers. MB was used as 
control. No toxicity was observed in the dark. In the assays 
without photosensitizer, ZnPc-loaded NPs and free photo-
sensitizer were replaced by empty NPs and PBS, respectively. 
The cell viability decreased with the increase in drug con-
centration (Figure 4). No significant difference (P . 0.05) in 
the photobiological activity of the encapsulated ZnPc was 
observed for the concentrations of 5 and 10 µg/mL. The pho-
totoxicity of the free ZnPc was not concentration dependent 
(Figure 4). The phototoxicity of the MB was observed only 
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Figure 2 A) In vitro releasing profile of the ZnPc from nanostructured system. B) graphic representation of the higuchi model obtained after regression. Mean and SD of 
n = 6 determinations.
Abbreviations: ZnPc, zinc phthalocyanine; SD, standard deviation.
Table 2 released drug in the acceptor solution and remaining 
content of photosensitizer in the nanoparticles
Released 
drug (%)1
Remaining drug in the 
nanoparticles (%)1
Total (%)2 Loss (%)2
22.1 ± 0.24 70.8 ± 0.48 92.9 7.1
Notes: 1Media ± standard deviation of n = 6 determinations; 2Media of n = 6 determinations.
Table 3 Determination coefficient (R2) and correlation coefficient 
(r) obtained after linear regression of the release data
Mathematical models R2 r
Zero order 0.9556 0.9775
First order 0.9663 0.9830
higuchi 0.9861 0.9932
Baker–Lonsdale 0.9782 0.9890
hixon–crowell 0.9629 0.9812
Square root of mass 0.9612 0.9824
Three seconds root of mass 0.9594 0.9794International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in 5 and 10 µg/mL. ZnPc-loaded NPs   exhibited phototoxicity 
significantly higher than free photosensitizers (P , 0.05) 
(Figure 4).
The influence of the light dose (J/cm2) on the photobio-
logical activity was evaluated using 5 µg of ZnPc (volume 
of 250 µL) and incubation time of 4 h. No toxicity was 
observed in the dark (without irradiation). Photobiological 
activity of the ZnPc-loaded NPs was observed at 10 J/cm2. 
The light dose increase was responsible for the improvement 
of the biological effect. The free ZnPc exhibited photobio-
logical activity in the light dose of 50–100 J/cm2. Phototoxic-
ity of the MB was observed at 20–100 J/cm2. Besides, 
ZnPc-loaded NPs exhibited a phototoxic effect significantly 
higher than free photosensitizers (P , 0.05) (Figure 5).
No morphological change was observed in cells treated 
with saline (control group) (Figure 6A, B) and empty NPs 
(no photosensitizer) (Figure 6C, D) after illumination with 
visible light (red light, 660 nm, for 90 sec, with light dose of 
100 J/cm2). The cells incubated with NPs containing ZnPc 
and irradiated with visible light showed morphological 
changes. Morphological alterations of the cell induced by 
photobiological action of ZnPc included the following 
changes: cytoplasmic condensation with significant reduction 
of cell volume, rarified cytoplasmic matrix, extensive cell lysis, 
and loss of plasma membrane extensions (Figure 6E, F).
As shown in Figure 7, the chemical measurements 
showed a significant decrease in the absorbance at 400 nm 
for ZnPc-loaded NPs with ABMDMA after irradiation, sug-
gesting a high efficiency in the generation of 1O2 (Figure 7). 
For the free ZnPc, the photobleaching caused by  1O2 was 
lower than that of ZnPc-loaded NPs. There was no decrease 
in the absorbance for a sample containing ABMDMA and 
empty NPs (Figure 7).
Discussion
NPs have been used as a possible method to target and control 
drug delivery, and prevent the side effects associated with 
undesirable biodistribution of the free form of drugs.11,15 
Moreover, there are many options for modifying the biodistri-
bution of NPs by appropriate selection of the polymer, surface 
modification (hydrophilic coating), and particle size.11 Among 
the morphofunctional features of solid tumors are the 
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Figure 3 Influence of the incubation time (h) in the phototoxicity of free ZnPc or ZnPc-loaded nanoparticles. The cells were incubated with 5 µg (250 µL) of free ZnPc and 
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abnormal function of the lymphatic vasculature, which causes 
fluid retention, and the increased permeability of blood vessel 
walls. Both these characteristics lead to a higher retention of 
NPs in the tumor area in comparison with normal tissues, 
resulting in a passive selectivity of the system.42 Thus, nano-
metric size, which is directly related to the technique of NPs 
obtention, is crucial for the desired tissue penetration.40
The size of the NPs obtained depends on many factors 
such as the stirring speed, solution viscosity, organic/aqueous 
phase ratio, and surfactant concentration in the external 
aqueous phase. In this study, the use of solvent emulsification-
evaporation method (SEEM) associated with sonication 
produced the photosensitizer-loaded NPs of appropriate size. 
NPs containing photosensitizer were produced with success 
using PCL by SEEM. The encapsulation method produced 
particles in nanometric scale (,200 nm) with narrow size 
distribution (IP , 0.1), spherical shape, and excellent EE 
(.60%). The low release depends on the nature of both the 
polymer and the encapsulated molecule.38 ZnPc presented a 
low and sustained release. The release data were fitted using 
the mathematical models of zero order, first order, Higuchi, 
Hixon–Crowell, square root of mass, three seconds root of 
mass, and Baker–Lonsdale. Zero-order kinetics can be used 
to describe the drug release from several types of delivery 
systems such as matrix tablets for drugs with low solubility44 
and osmotic systems where drug release would be directly 
proportional to time. The first-order model describes the 
release profile from the delivery systems containing drugs 
dispersed in porous matrices where drugs would be released 
at rates proportional to the amount of drug remaining in the 
interior of the delivery system.36 Hixon and Crowell recog-
nized that the particle regular area is proportional to the cubic 
root of its volume.45 This relationship between area and 
volume plus the release and remaining amount of the drug 
can influence the release kinetics. The shape factor for cubic 
or spherical particles should be kept constant if the particles 
are dissolved in an equal manner on all sides. When this 
model is used, it is assumed that the release rate is limited 
by the drug particle dissolution rate and not by the diffusion 
that might occur through the polymeric matrix.45   
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Figure 4 Influence of the photosensitizer concentration in the photobiological activity of free ZnPc, free MB, or ZnPc-loaded nanoparticles. The cells were incubated with 
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The Baker–Lonsdale model was developed from the Higuchi 
model and describes drug controlled release from a spherical 
matrix.46 This mathematical model has been used for linear-
ization of release data from several formulations of micropar-
ticles and NPs. The mathematical models of squared root and 
three seconds root of mass were also tested in the release 
kinetic study.36,37 The Higuchi model has been based on the 
Fick’s law where the release occurs by the diffusion of drugs 
within the delivery system.36,47 In this case, the released 
amount of the drug is proportional to the square root of time. 
The   Higuchi model gave the highest value of R2 and r, indi-
cating that this mathematical model was the most suitable 
for describing the release of the photosensitizer from PCL 
NPs (Table 3). These results suggest that the release of ZnPc 
from PCL NPs is controlled by diffusion. From these results, 
the mechanism of the photosensitizer release from PCL NPs 
can be considered as follows: 1) Water penetrates into poly-
meric matrix of the NPs through pores, slowly dissolving the 
photosensitizer. 2) ZnPc is released by diffusion into acceptor 
  solution. 3) The photosensitizer is hydrophobic and accumu-
lates into SDS micelles.
The in vitro phototoxicity studies showed that the 
ZnPc-loaded NPs were more phototoxic than the free ZnPc 
(  Figures 3–5). The photobiological activity is highly depen-
dent on the photosensitizer’s cellular uptake mechanism and 
its subcellular localization. In aqueous medium, a free lipo-
philic photosensitizer is generally absorbed by diffusion 
across the plasmatic membrane (lipophilic) leading to a low 
intracellular concentration. Moreover, lipophilic photosen-
sitizers such as ZnPc tend to aggregate in aqueous medium 
with reduction of its photodynamic activity.48 Due to its 
instability in water, the photobiological activity of the free 
ZnPc was not concentration dependent (Figure 4). The MB 
was less phototoxic than the ZnPc-loaded NPs (P , 0.05) 
(  Figures 3–5). MB is hydrophilic and has difficulty in cross-
ing the lipophilic membrane of the cells, leading to a low 
intracellular concentration. However, NPs are able to enter 
the cells by endocytosis, releasing the photosensitizer in the 
cell cytoplasm. The intracellular localization of the photo-
sensitizer, an important factor in PDT, can induce different 
damage in the cells. Due to its hydrophobic characteristics, 
intracellular ZnPc is able to accumulate in the cytoplasmic 
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membrane, lysosomal compartment, and mitochondria. 
Intracellular generation of 1O2 and additional free radicals 
can act as potent cytotoxic agents.
The 1O2 is the main toxic species generated by phtha-
locyanines during PDT.49 The photobleaching studies 
(  Figure 7) are in agreement with the photobiological activity 
results (  Figures 3–5). ZnPc-loaded NPs generated 1O2 more 
  efficiently than free ZnPc (Figure 7). The free ZnPc suffers 
aggregation in water leading to a low 1O2 generation.   However, 
encapsulation in NPs protected the ZnPc from the aggregation 
in aqueous medium. Due to slow release (  Figure 2), many 
ZnPc molecules can remain adsorbed on the surface of the NPs. 
The adsorbed photosensitizer can be activated by red light 
leading to a strong 1O2 generation. The photobleaching data 
are consistent with those obtained by Zhao et al.50 The 1O2 
generation was improved after encapsulation of the   lipophilic 
photosensitizer (silicon phthalocyanine (SiPc)) in silica NPs. 
SiPc is a lipophilic photosensitizer. It aggregates in aqueous 
solution, which reduces its therapeutic efficacy and limits its 
clinical use.50 Zhao et al have encapsulated SiPc using silica 
NPs, which not only improves the aqueous stability but also 
increases its 1O2 generation and photobiological activity com-
pared with free SiPc.50 SiPc-loaded silica NPs generated 
photo-induced 1O2 more efficiently than free SiPc.50
The results obtained from in vitro phototoxicity studies 
demonstrated that the phototoxicity of ZnPc against the 
A549 cells occurred after 24 h of light exposure because the 
cellular damage resulting from the photochemical reaction 
is not immediately lethal. This phenomenon could be due to 
an apoptotic response, which is a slow process.5 Cell death 
by necrosis3 may occur on a smaller scale. Necrosis is a 
drastic process of death that results in cell lysis.
Conclusion
Nanotechnology is bringing new perspectives to a number of 
fields of human knowledge. Its applications in cancer treat-
ment by PDT are being investigated largely with excellent 
results. The nanoencapsulation was suitable for the prepara-
tion of PCL NPs because the release system has nanometric 
size, narrow distribution, regular shape, and sustained release. 
Achieving optimal effect of PDT on tumor cells requires that 
the photosensitizer becomes closely associated to the subcel-
lular organelles. Encapsulation of ZnPc in the PCL NPs 
improved its stability in aqueous medium and the in vitro 
phototoxicity. The photobiological activity was influenced 
by photodynamic parameters such as incubation time, light 
dose, and drug concentration. Based on all the photobiological 
measurements, it can be concluded that the ZnPc-loaded PCL 
NPs are promising delivery systems for use in PDT.
Acknowledgments
We thank the financial support of Conselho Nacional d 
Desenvolvimento Científico e Tecnológico (CNPq) and 
A B
C D
200 µm 50 µm
200 µm 50 µm
200 µm 50 µm
E F
Figure  6  Morphological  evaluation  of  the  A549  cells  using  light  microscope: 
A) and B) cells incubated with PBS (control). C) and D) cells incubated with empty 
nanoparticles suspension. E) and F) cells incubated with ZnPc-loaded nanoparticles. 
(A), (C), and (E) were observed at magnification of ×50 (scale 200 µm). (B), (I), and 
(F) were observed at magnification of ×400 (scale 50 µm).
Abbreviations: PBS, phosphate-buffered saline; ZnPc, zinc phthalocyanine.
0
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
50 100
ZnPc-loaded in nanoparticles Free ZnPc Empty nanoparticles
150 200
Time (s)
A
b
s
o
r
b
a
n
c
e
 
i
n
 
4
0
0
 
n
m
250 300 350 400
Figure 7 Photobleaching of ABMDMA by singlet oxygen generated by encapsulated 
ZnPc and free ZnPc. empty nanoparticles were used as control. The change in 
ABMDMA absorption at 400 nm was measured as a function of the irradiation time. 
each data point represents the mean (±SD) of n = 3 determinations.
Abbreviations:  ABMDMA,  9,10-anthracenediyl-bis(methylene)dimalonic  acid; 
ZnPc, zinc phthalocyanine; SD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
237
Nanostructured delivery system for zinc phthalocyanine
Fundação Carlos Chagas Filho de Amparo à Pesquisa do 
Estado do Rio de Janeiro (FAPERJ).
Disclosure
The authors report no conflict of interest in this work.
References
  1.  Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH. 
Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther. 
2004;1:27–42.
  2.  Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-
Heyob M. Nanoparticles as vehicles for delivery of photodynamic 
therapy agents. Trends Biotechnol. 2008;26(11):612–621.
  3.  Castano AP, Demidova TN, Hamblin MR. Mechanisms in photody-
namic therapy: Part three – Photosensitizer pharmacokinetics, biodis-
tribution, tumor localization, and modes of tumor destruction. 
Photodiagnosis Photodyn Ther. 2005;2(2):91–106.
  4.  Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic 
therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60(15): 
1627–1637.
  5.  Zhou C, Shunji C, Jinsheng D, Junlin L, Jori G, Milanesi C. Apoptosis 
of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy 
with Zn (II)-phthalocyanine. J Photochem Photobiol B. 1996;33(3): 
219–223.
  6.  Bonnett R. Photosensitizers of the porphyrin and phthalocyanine series 
for photodynamic therapy. Chem Soc Rev. 1995;26(37):19–33.
  7.  Savolainen J, van der Linden D, Dijkhuizen N, Herek JL. Characterizing 
the functional dynamics of zinc phthalocyanine from femtoseconds to 
nanoseconds. J Photochem Photobiol A Chem. 2008;196(1):99–105.
  8.  Zanfolim AA, Volpati D, Olivati CA, Job AE, Constantino CJL. Struc-
tural and electric-optical properties of zinc phthalocyanine evaporate 
in films: temperature and thickness effects. J Phys Chem. 2010;114(28): 
12290–12299.
  9.  Ricci-Júnior E, Marchetti JM. Preparation, characterization, photocy-
totoxicity assay of PLGA nanoparticles containing zinc (II) phthalo-
cyanine for photodynamic therapy use. J Microencapsul. 2006;23(5): 
523–538.
  10.  Wainwright M, Phoenix DA, Rice L, Burrow SM, Waring J. Increased 
cytotoxicity and phototoxicity in the methylene blue series via 
  chromophore methylation. J Photochen Photobiol B. 1997;40(3): 
233–239.
  11.  Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery 
and targeting. Curr Opin Solid State Mater Sci. 2002;6(4):319–327.
  12.  Camerin M, Magaraggia M, Soncin M, et al. The in vivo efficacy of 
phthalocyanine–nanoparticle conjugates for the photodynamic therapy 
of amelanotic melanoma. Eur J Cancer. 2010;46(10):1910–1918.
  13.  Murthy SK. Nanoparticles in modern medicine: state of the art and 
future challenges. Int J Nanomedicine. 2007;2(2):129–141.
  14.  De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications 
and hazards. Int J Nanomedicine. 2008;3(2):133–149.
  15.  Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. 
  Biodegradable polymeric nanoparticles as drug delivery devices.   
J Control Release. 2001;70(1–2):1–20.
  16.  Ungun B, Prud’homme RK, Budijon SJ, et al. Nanofabricated upcon-
version nanoparticles for photodynamic therapy. Opt Express. 2009; 
17(1):80–86.
  17.  Allison RR, Mota HC, Bagnato VS, Sibata CH. Bio-nanotechnology 
and photodynamic therapy–state of the art review. Photodiagnosis 
Photodyn Ther. 2008;5(1):19–28.
  18.  Konan YN, Berton M, Gurny R, Allemann E. Enhanced photodynamic 
activity of meso-tetra(4-hydroxyphenyl)porphyrin by incorporation 
into sub-200 nm nanoparticles. Eur J Pharm Sci. 2003;18(3–4): 
241–249.
  19.  Konan YN, Chevallier J, Gurny R, Allemann E. Encapsulation of 
p-THPP into nanoparticles: cellular uptake, subcellular localization and 
effect of serum on photodynamic activity. Photochem Photobiol. 
2003;77(6):638–644.
  20.  Gomes AJ, Lunardi LO, Marchetti JM, Lunardi CN, Tedesco AC. 
Photobiological and ultrastructural studies of nanoparticles of 
poly(lactic-co-glycolic acid)-containing bacteriochlorophyll-a as a 
photosensitizer useful for PDT treatment. Drug Deliv. 2005;12(3): 
159–164.
  21.  Konan-Kouakou YN, Boch R, Gurny R, Allemann E. In vitro and 
in vivo activities of verteporfin-loaded nanoparticles. J Control Release. 
2005;103(1):83–91.
  22.  Tang W, Xu H, Kopelman R, Philbert MA. Photodynamic characteriza-
tion and in vitro application of methylene blue-containing nanoparticle 
platforms. Photochem Photobiol. 2005;81(2):242–249.
  23.  Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded 
nanoparticles for the photodynamic treatment of ovarian cancer. Int J 
Pharm. 2006;326(1–2):174–181.
  24.  Allemann E, Rousseau J, Brasseur N, Kudrevich SV, Lewis K, van 
Lier JE. Photodynamic therapy of tumours with hexadecafluoro zinc 
phthalocyanine formulated in PEG-coated poly(lactic acid) nano-
particles. Int J Cancer. 1996;66(6):821–824.
  25.  Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog 
Polym Sci. 2007;32(8–9):762–798.
  26.  Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-ε-
caprolactone microspheres and nanosperes: an overview. Int J Pharm. 
2004;278(1):1–23.
  27.  Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanopar-
ticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010; 
75(1):1–18.
  28.  verger ML, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation 
and characterization of nanoparticles containing an antihypertensive 
agent. Eur J Pharm Biopharm. 1998;46(2):137–143.
  29.  Ferranti V, Marchais H, Chabenat C, Orecchioni AM, Lafont O. 
Primidone-loaded poly-ε-caprolactone nanocapsules: incorporation 
efficiency and in vitro release profiles. Int J Pharm. 1999;193(1): 
107–111.
  30.  Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres com-
posed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) 
as novel anticancer drug carriers. Biomaterials. 2001;22(13): 
1697–1704.
  31.  Zili Z, Sfar S, Fessi H. Preparation and characterization of poly-ε-
caprolactone nanoparticles containing griseofulvin. Int J Pharm. 2005; 
294(1–2):261–267.
  32.  Shenoy DB, Amiji MM. Poly(ethylene-oxide)-modified poly(ε-
caprolactone) nanoparticles for targeted delivery of tamoxifen in breast 
cancer. Int J Pharm. 2005;293(1–2):261–270.
  33.  Blouza IL, Charcosset C, Sfar S, Fessi H. Preparation and characteriza-
tion of spironolactone-loaded nanocapsules for pediatric use. Int J 
Pharm. 2006;325(1–2):124–131.
  34.  Prabu P, Chaudhari AA, Dharmaraj N, Khil MS, Park SY, Kim HY. 
Preparation, characterization, in-vitro drug release and cellular uptake 
of poly(caprolactone) grafted dextran copolymeric nanoparticles 
loaded with anticancer drug. J Biomed Mater Res. 2009;90(4): 
1128–1136.
  35.  Zheng D, Li X, Xu H, Lu X, Hu Y, Fan W. Study on docetaxel-loaded 
nanoparticles with high antitumor efficacy against malignant melanoma. 
Acta Biochim Biophys Sin. 2009;41(7):578–587.
  36.  Costa P, Sousa Lobo JM. Modeling and comparison of dissolution 
profiles. Eur J Pharm Sci. 2001;13(2):123–133.
  37.  Barzegar-Jalali M, Adibkia K, Valizadeh H, et al. Kinetic analysis of 
drug release from nanoparticles. J Pharm Pharm Sci. 2008;11(1): 
167–177.
  38.  Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous 
tumor-cell line from a human lung carcinoma with properties of 
type II alveolar epithelial cells. Int J Cancer. 1976;17(1):62–70.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology in 
diagnostics, therapeutics, and drug delivery systems throughout the 
biomedical field. This journal is indexed on PubMed Central, MedLine, 
CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal 
Citation Reports/Science Edition, EMBase, Scopus and the Elsevier 
Bibliographic databases. The manuscript management system is 
completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
238
da Volta Soares et al
  39.  Mosmann T. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods. 
1983;65(1–2):55–63.
  40.  Veiga VF, Nimrichter L, Teixeira CA, et al. Exposure of human 
  leukemic cells to direct electric current: generation of toxic compounds 
inducing cell death by different mechanisms. Cell Biochem Biophys. 
2005;42(1):61–74.
  41.  Lindig BA, Rodgers MAJ, Schaap AP. Determination of the lifetime 
of singlet oxygen in D2 using 9,10-anthracenedipropionic acid, a water-
soluble probe. J Am Chem Soc. 1980;102(17):5590–5593.
  42.  Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, 
Farokhzad OC. New frontiers in nanotechnology for cancer treatment. 
Urol Oncol. 2008;26(1):74–85.
  43.  Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific 
nanoparticle delivery: effect of particle size. Cancer Res. 2000; 
60(16):4440–4445.
  44.  Tanaka N, Imai K, Okimoto K, et al. Development of novel sustained-
release system, disintegration-controlled matrix tablet (DCMT) with 
solid dispersion granules of nilvadipine. J Control Release. 2005; 
108(2–3):386–395.
  45.  Hixson AW, Crowell JH. A simple model based on first order kinetics 
to explain release of highly water. Ind Eng Chem Res. 1931;23: 
923–931.
  46.  Baker RW, Lonsdale HS. Controlled Release of Biologically Active 
Agents. Tanquary AC, Lacey RE, editors. New York, NY: Plenum 
Press; 1974.
  47.  Higuchi T. Mechanism of sustained-action medication: theoretical 
analysis of rate of release of solid drugs dispersed in solid matrices.   
J Pharm Sci. 1963;52:1145–1149.
  48.  Isele U, Schieweck K, Kessler R, van Hoogevest P, Capraro HG. 
Pharmacokinetics and body distribution of liposomal zinc phthalocya-
nine in tumor-bearing mice: influence of aggregation state, particle size, 
and composition. J Pharm Sci. 1995;84(2):166–173.
  49.  Allen CM, Sharman WM, van Lier JE. Current status of phthalocyanines 
in the photodynamic therapy of cancer. J Porphyr Phthalocyanines. 
2001;5:161–169.
  50.  Zhao B, Yin JJ, Bilski PJ, Chignell CF, Roberts JE, He Y-Y. Enhanced 
photodynamic efficacy towards melanoma cells by encapsulation of 
Pc4 in silica nanoparticles. Toxicol Appl Pharmacol. 2009;241(2): 
163–172.